UBS analyst Karl Keirstead raised the firm’s price target on Confluent to $39 from $24 and keeps a Neutral rating on the shares. At the company’s first post-IPO analyst day, Confluent modestly trimmed its medium-term revenue growth outlook and revised its margin outlook higher, and spoke to the way it’s poised to benefit from augmenting LLMs with real-time data, the analyst tells investors in a research note. The firm says the analyst day won’t serve as a material catalyst for the stock from current valuation levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CFLT:
- Confluent price target raised to $41 from $35 at Wells Fargo
- Confluent downgraded to Neutral from Buy at Guggenheim
- Confluent price target raised to $41 from $31 at JMP Securities
- Confluent price target raised to $42 from $26 at Barclays
- Confluent price target raised to $43 from $36 at MoffettNathanson